ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

Therapeutic Modalities Improve Patient Quality of Life In Trials

February 27, 2004

Neutron Therapy “Treatment Of Choice” In Salivary Gland Tumors – 100 Percent Complete Reponses

June 13, 1986

NCAB Puts 20% Cap On P01 Budget Raises To Stem Requests Exceeding NCI’s.

February 25, 2000

Paraplatin Lengthened TTP In HER2+ Advanced Breast Ca

January 31, 2003

Nimer to Lead Miami Sylvester Cancer Center

March 9, 2012

St. Jude Offers Two Fellowships

July 18, 1986